Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Ribi ImmunoChem offers licenses for cardioprotectant

May 19, 1997

Antiproliferative effects of PCA-4230 in vascular smooth muscle cells

May 16, 1997

SmithKline Beechan to market Kissei's tranilast

May 15, 1997

Antiischemic potassium channel activators described by BMS

May 15, 1997

Selective alpha1b-adrenoceptor blockers from Merck & Co.

May 14, 1997

ET antagonists described by Ciba-Geigy Japan (Novartis)

May 12, 1997

FDA approves Mylan's generic extended-release diltiazem

May 9, 1997

Mibefradil evaluated for impact on mortality in large CHF trial

May 8, 1997

ANDA filed for Biovail generic calcium channel blocker

May 7, 1997

Potent and selective ETA antagonists from Shionogi

May 7, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...